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1. Introduction
Serotonin or 5-hydroxytryptamine (5-HT) is a well-established monoamine 
neurotransmitter in the central nervous system (CNS). The discovery of 5-HT dates as 
far back as 1868 and can be traced to its presence in the blood and in the gastrointesti-
nal tract [1]. Its well-known biological functions include modulating cognition, sleep, 
emotion, learning, memory, and numerous physiological processes. 5-HT is primarily 
found in the enteric nervous system located in the gastrointestinal tract [2], where it 
Figure 1. 
Model explaining PLA2 activation in response to serotonergic drugs. Under normal conditions, the 5-HT 
that is released from presynaptic vesicles into the synaptic cleft binds to postsynaptic 5-HT receptors coupled 
via a G-protein to PLA2, thus hydrolyzing arachidonic acid (AA) from membrane phospholipids (PL). 
Administration serotonergic drugs activate PLA and increase incorporation of AA by different routes. 
(1) 5-HT2A/2C agonist, DOI directly binds to 5-HT2 receptors to activate this signal; (2) fluoxetine (SSRI) 
inhibits 5-HT uptake, thus increasing 5-HT in the synaptic cleft so as to increase PLA activation and 
AA release. This figure adapted from [23].
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regulates intestinal movements [2], and the remainder is synthesized in the serotoner-
gic neurons of the CNS, where it has various functions such as the regulation of mood, 
appetite, and sleep. Modulation of 5-HT at synapses is thought to be a major action of 
several classes of pharmacological antidepressants. Among these, selective serotonin 
reuptake inhibitors (SSRIs), such as fluoxetine and citalopram, are the most important 
class of antidepressant in the treatment of major depressive disorder (MDD) and anxi-
ety disorders [3]. The exact mechanism of action of SSRIs is not fully revealed. SSRIs 
are able to increase the extracellular level of the neurotransmitter 5-HT by inhibiting 
its reuptake into the presynaptic terminal, increasing the level of 5-HT in the synaptic 
cleft available to bind to the postsynaptic 5-HT receptor (as shown in Figure 1). SSRIs 
have different degrees of selectivity for the other monoamine transporters, and the 
most selective SSRI has weak affinity for the norepinephrine and dopamine transport-
ers. They are the most widely prescribed antidepressants in many countries, and their 
efficacy in mild or moderate cases of depression has been disputed [4] and may be 
outweighed by side effects [3]. I have been involved in 5-HT research for two decades. 
This chapter summarized my research on 5-HT-related projects from measuring 
5-HT concentration, attempting to discover a new generation of SSRIs to investigate 
5-HT-regulated post-receptor signaling transduction. This chapter also discusses some 
perspectives research that is important for SSRI and depression treatment.
2. Measuring serotonin in CNS system
In the early 1990s, liquid chromatography (LC) with an electrochemical detec-
tor (ED) had been widely used for the measurement of neurochemicals [5]. The 
first 5-HT project that I worked with was to develop a method for measuring 5-HT 
concentration in chicken brain tissue [6]. An isocratic LC-ED for the determina-
tion of L-3,4-dihydroxyphenylalanine, dopamine, norepinephrine, epinephrine, 
5-HT, and their major metabolites, 3,4-dihydroxyphenylacetic acid, 4-hydroxy-
3-methoxyphenylacetic acid, and 5-hydroxyindole-3-acetic acid in chicken brain 
tissue was developed in our lab. The method was applied to study the influence of 
food restriction on the concentration of 5-HT and other monoamine neurotransmit-
ters in different brain areas, known to be involved in the feeding and reproductive 
behavior of female broiler chickens. In the experiment, two to six micropunches 
from 20 different brain areas on 300 μm cryostat brain section were punched out 
and expelled into Eppendorf for homogenization and extraction. Supernatant was 
injected onto LC-ED, and over 1000 micro-punched tissue samples from ad libitum 
fed and food-restricted female broiler chickens were analyzed. Tissue pellets were 
dissolved in PBS buffer for protein content determination to express the results as 
pg monoamine/μg protein. Although the concentration of monoamines in the brain 
is not high, multiple tissue micropunches made enough amount of monoamine and 
5-HT to match the sensitivity of the assay. Our results provided a possible role for 
catecholamines and indolamines in the altered feeding and reproductive behavior of 
the broiler chicken [6]. To finish my Ph.D. thesis, I modified this method to measure 
5-HT and other monoamine neurotransmitters in cat visual cortex [7]. The role of 
monoaminergic neuromodulators in the reorganization of cortical topography fol-
lowing limited sensory deprivation in the adult cat was investigated in this study [8]. 
The total concentrations of dopamine, noradrenaline, 5-HT, and their major metabo-
lites were measured in the visual cortex of both control and experimental animals 
using this microbore LC-ED method. The sensory deprivation cats were subjected 
to a binocular retinal lesion corresponding to the central 10 degrees of vision and 
sacrificed 2 weeks post-lesion. The deprivation was confirmed in area 17 by measur-
ing immediate-early gene if-268 messenger RNA expression. The total concentration 
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of 5-HT was significantly lower in the deprived cortex, and the metabolite of 5-HT, 
5-hydroxyindole-3-acetic acid, was significantly higher in the nondeprived cortex 
than in deprived cortex and normal cortex. The levels of noradrenaline and dopa-
mine were significantly higher in the nondeprived cortex of retinal lesion cats than 
in the deprived cortex of retinal lesion cats and the cortex of normal animals. This 
pattern follows the release of the excitatory neurotransmitter glutamate under the 
same conditions. These results suggest that the modulation of 5-HT, noradrenaline, 
and dopamine is regulated by visual afferent activity [8].
To switch my scientific career to the pharmaceutical industry, I joined the 
CNS drug discovery team for making a new generation dual function SSRI [9] for 
depression treatment. Fluoxetine (Prozac) [10] is the first SSRI and widely used for 
the treatment of depression which was used as reference compounds for new SSRI 
discovery. Fluoxetine exerts its behavioral and clinical therapeutic effect by block-
ing the transport of 5-HT at the serotonin reuptake transporter (SERT), thereby 
increasing extracellular level of 5-HT in the serotonergic synaptic cleft of many 
brain regions as shown in Figure 1. In vivo microdialysis has been extensively used 
to document the changes of extracellular level of 5-HT in the rat brain after admin-
istration of fluoxetine [11]. Therefore, we designed a 21-hour in vivo microdialysis 
experiment and the effect of acute systemic administration of fluoxetine (3 and 
10 mg/kg s.c.) on extracellular level of 5-HT in the frontal cortex of freely moving 
rats was analyzed by LC with ESA CoulArray coulometric detector (an electro-
chemical detector) [9, 12]. In this experiment, the guide cannula was implanted 
on rats’ brain by surgery and secured in place with skull screws and dental cement. 
Animals were allowed at least 3 days to recover from surgery prior to experimenta-
tion. Dialysis probes were perfused with artificial cerebral spinal fluid (aCSF, 
47 mM NaCl, 4 mM KCl, 0.85 mM MgCl2, 2.3 mM CaCl2, pH 7.4) at a flow rate of 
1 μL/min. Samples were collected every 60 min. Microdialysates were analyzed by 
LC-ED. Separation was performed on a C18 column. All values for microdialysis 
studies were calculated as percentage change at each time point compared with the 
average of three baseline values. Due to the limitation of low recovery of microdi-
alysis probe (less than 20% in average) and low concentration of 5-HT in the frontal 
cortex of rat brain (about 100 fg/μL in this microdialysates), high sensitivity ana-
lytical tool is required. LC-ED was the most popular method to measure 5-HT. In 
recent years, liquid chromatography with tandem mass spectrometry (LC-MS/MS) 
was also used for this purpose [13].
Pharmacokinetic (PK) characterization and in vivo pharmacological proper-
ties of new chemical entities are important components during lead compound 
selection and optimization in the drug discovery process. Accordingly, reliable 
techniques are needed that can generate the requisite pharmacokinetic/pharma-
codynamic (PK/PD) information for an increased number of compounds. When 
dealing with compounds targeting the central nervous system (CNS), biophase 
PK may differ significantly from plasma PK, because blood-brain barrier (BBB) 
transport and brain distribution often do not occur instantaneously and to a full 
extent. In vivo microdialysis technique can be used to collect not only the extracel-
lular endogenous substances but also the extracellular free drug in the same local 
interstitial environment, which may reflect the amount of drug available at the 
pharmacological target. However, the application of this technique was highly 
limited by the lack of the proper sensitive analytical methods to determine the 
endogenous substance and exogenous drug. LC-MS/MS technique improvement 
provides a direct, structural-specific measurement of individual components with 
very high sensitivity. The mass spectrometer has minimal baseline drift and can be 
equilibrated very rapidly. For this purpose, we have developed a series of LC-MS/
MS methods, which enable us to monitor drug, citalopram, and 5-HT in the same 
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microdialysis samples [13]. These applications demonstrated in vivo microdialysis 
coupled with LC-MS/MS is a very important tool to evaluate the PK/PD relationship 
by comparing the time course of free drug versus biomarker. LC-MS/MS method 
measuring 5-HT concentration in the brain is possible, but not widely applied [13].
3. Evaluating PK/PD profile of the dual function SSRI
The World Health Organization (WHO) estimates that more than 300 mil-
lion individuals of all ages suffer from depression [14]. SSRIs have been the drugs 
for depression treatment. These drugs increase 5-HT levels in the synaptic cleft 
by inhibiting its reuptake into the presynaptic neuron through blockade of the 
SERT. Although many patients experience relief after treatment with one of the 
many marketed SSRIs, efficacy is noticeable only after weeks of treatment. Many 
physicians are reported to co-prescribe stimulants with SSRI to provide subjective 
relief during the beginning weeks of antidepressant therapy [15]. Most of these 
stimulants are increased dopamine release and produced robust behavioral activa-
tion, which had the risk of allowing patients to act on their suicidal ideation. It is 
very important to choose other classes of molecules that have been shown to produce 
wakefulness in animals without releasing dopamine or producing behavioral activa-
tion. Wake-promoting agents such as modafinil are used in the clinic as adjuncts to 
antidepressant therapy in order to alleviate lethargy. Histamine H3 receptor antago-
nist has been demonstrated having the wake-promoting action in numerous animal 
studies and may therefore be a viable strategy for use as an antidepressant therapy 
in conjunction with SSRIs. Therefore, some potential antidepressant molecules were 
created, which combined the wake-promoting effect of a histamine H3 receptor 
antagonist with 5-HT reuptake blockage effects of SERT inhibitor [9]. The synthetic 
approach and structure-activity relationships associated with this effort have been 
studied [16–18]. In vivo microdialysis experiments were used to examine whether 
a compound was capable of inducing a robust and persistent increase in 5-HT level 
over baseline. One of these molecules, JNJ-28583867 (2-methyl-4-(4-methylsulfanyl-
phenyl)-7-(3-morpholin-4-yl-propoxy)-1,2,3,4-tetrahydro-isoquinoline), is a 
selective and potent histamine H3 receptor antagonist (Ki = 10.6 nM) and inhibitor 
of the SERT (Ki = 3.7 nM), with 30-fold selectivity for SERT over the dopamine and 
norepinephrine transporters [9]. After subcutaneous administration, JNJ-28583867 
significantly increased cortical extracellular levels of 5-HT as shown in Figure 2A. 
Baseline measurements of 5-HT levels were performed for 4 h prior to administra-
tion of JNJ-28583867. At all doses, 5-HT levels remained elevated for the duration 
of the experiment up to 18 h after dosing. JNJ-28583867 was also tested in a classical 
test of antidepressant activity, the mouse tail suspension model. As was expected 
based on the neurochemical profile of JNJ-28583867, an increase in struggling time 
was observed. Some PK characterization of JNJ-28583867 was carried out in the rat. 
The behavioral experiments had indicated good oral bioavailability and this was 
confirmed. The half-life correlates well with the observation that effects could be 
observed up to 24 h after a single oral dose, as was the case in the head twitch test. 
The plasma and brain levels of JNJ-28583867 are sustained and correlated reasonably 
well with efficacy for an extended period of time as shown in Figure 2B [9]. Similar 
PK/PD profiles were observed from norfluoxetine, which is the metabolite of refer-
ence SSRI, fluoxetine [12]. Norfluoxetine is the most important active metabolite of 
the widely used antidepressant fluoxetine. Following subcutaneous administration 
of fluoxetine in rats, plasma, and brain PK of fluoxetine and norfluoxetine were 
monitored, respectively, by LC-MS/MS. The extracellular level of 5-HT in the frontal 
cortex was measured by microdialysis as a PD endpoint. Norfluoxetine when directly 
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administrated to rats caused a significant increase in the extracellular level of 5-HT 
in the frontal cortex and maintained for 18 hours as shown in Figure 2C. This result 
is correlated well with higher plasma and brain concentration and longer plasma and 
brain retention time of norfluoxetine (as shown in Figure 2D) [12]. In summary, 
these studies have shown that the combination of histamine H3 receptor antagonism 
with SSRI activity in a single molecule results in a pharmacology consistent with the 
combination of either class of molecule alone. JNJ-28583867 can be a prototype of 
such a compound to improve current SSRI efficacy and safety profiles [9].
4. Serotonin-mediated post-receptor signaling transduction
Although antidepressants are generally effective in the treatment of MDD, side 
effects still exist. Serotonin syndrome is a potentially life-threatening adverse drug 
reaction that results from therapeutic drug use and a predictable consequence of 
excess serotonergic agonism of CNS and peripheral serotonergic receptors [19]. 
In 2002, the Toxic Exposure Surveillance System, which receives case descrip-
tions from office-based practices, inpatients settings, and emergency department, 
reported 26,733 incidences of exposure to SSRIs that caused significant toxic effects 
in 7349 persons and resulted in 93 deaths [19, 20]. The development mechanism of 
serotonin syndrome is unknown. It is hypothesized that the level of 5-HT elevation 
Figure 2. 
(A). Effect of JNJ-28583867, administered s.c., on extracellular 5-HT levels in the frontal cortex of male 
Sprague-Dawley rats. Microdialysis time course. Results are expressed as the average ± S.E.M. of n = 3–6 rats 
per group. (B). Plasma levels of JNJ-28583867 after oral (10 mg/kg, square), intravenous (1 mg/kg, triangle), 
and subcutaneous (10 mg/kg, circle) administration to the rat. Results are shown as the average ± S.D. of 
n = 2–3 samples. (C). Effect of norfluoxetine on the extracellular level of 5-HT in the frontal cortex of free 
moving rat. Values are mean ± S.E.M. of extracellular 5-HT levels and expressed as a percentage of the 
average of three baseline samples (defined as 100%). Two-way ANOVA-post-hoc Duncan’s multiple range 
tests were used for comparison. Control (n = 5), 3 mg/kg (n = 6), and 10 mg/kg (n = 6) norfluoxetine were 
subcutaneously administrated. Asterisks indicate significance of overall effect of drug treatment versus vehicle, 
P < 0.01. (D). Time course of plasma concentrations of fluoxetine and norfluoxetine. Plasma concentrations 
(mean ± S.E., n = 10) of norfluoxetine were measured following subcutaneous administration of 3 or 10 mg/kg 
fluoxetine. Figure 4A and B was adapted from [9]; Figure 4C and D was adapted from [12].
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in blood plasma has to be 10–15% above the baseline levels to result in 5-HT toxicity 
[21]. Several lines of evidence converge to suggest that agonism of 5-HT2A receptors 
contributes substantially to the condition [22].
To address this question, we studied 5-HT-mediated post-receptor signaling 
transduction [23]. The 5-HT2 receptor is G protein-coupled receptor and is recog-
nized to be coupled to the phospholipase A2 (PLA2) signaling pathway, stimulating 
the release of the second messenger, arachidonic acid (AA). This signaling pathway 
is illustrated in Figure 1. PLA2 activation can be initiated by serotonergic 5-HT2 
receptors via a G-protein. The in vivo fatty acid methods were developed in our 
lab to measure regional brain incorporation of a radiolabeled fatty acid, including 
[5,6,8,9,11,12,14,15-3H] arachidonic acid (3H-AA) in conscious rats. Tracer incorpo-
ration, represented as the incorporation coefficient k*, reflects PLA2-mediated AA 
release. Activation of PLA2 in the brain is revealed as increments in k* in different 
receptors or to change serotonergic neurotransmission (Figure 1). The fatty acid 
method can be used to evaluate serotonergic neurotransmission mediated by PLA2 
in awake rats. It can quantify and localize brain PLA2 signaling in response to differ-
ent drugs administered acutely or chronically.
In rats, 2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI), which is a 5-HT2A/2C 
receptor agonist, provokes head twitches, skin jerks, and forepaw tapping, behaviors 
that are considered part of a “5-HT syndrome” [24]. The responses usually appear 
at a dose of 1.0 mg/kg and peak at 2.5 mg/kg. In one of our studies, DOI, when 
administered to unanesthetized rats, produced widespread and significant increases, 
of the order of 60%, in k* for arachidonate, particularly in neocortical brain regions 
reported to have high densities of 5-HT2A receptors [25]. The increases could be 
entirely blocked by chronic pretreatment with mianserin, a 5-HT2 receptor antago-
nist, which is an atypical antidepressant [25]. The results suggest that the 5-HT2 
syndrome involves widespread brain activation of PLA2 via 5-HT2A receptors, leading 
to the release of the second messenger, arachidonic acid. Chronic mianserin, a 5-HT2 
antagonist, prevents this activation [25]. In another study, brain PLA2-mediated 
signal transduction in response to acute fluoxetine administration in unanesthetized 
rats had been imaged [26]. By inhibiting presynaptic 5-HT reuptake, fluoxetine is 
thought to act by increasing 5-HT in the synaptic cleft, thus 5-HT binding to postsyn-
aptic 5-HT2A/2C receptors, activates PLA2 pathway, and releases the second messenger 
AA from synaptic membrane phospholipids. To image this activation, fluoxetine 
(10 mg/kg) or saline vehicle was administered i.p. to unanesthetized rats, and 
regional brain incorporation coefficients k* of intravenously injected radiolabeled 
AA were measured after 30 min. Compared with vehicle, fluoxetine significantly 
increased k* in prefrontal, motor, somatosensory, and olfactory cortex, as well as in 
the basal ganglia, hippocampus, and thalamus. Many of these regions demonstrate 
high densities of the SERT and of 5-HT2A/2C receptors. The brain stem, spinal cord, 
and cerebellum, which showed no significant response to fluoxetine, have low densi-
ties of the transporters and receptors. The results show that it is possible to image 
quantitatively PLA2-mediated signal transduction in vivo in response to fluoxetine 
[26]. Fluoxetine’s therapeutic action when chronically administered has been ascribed 
to desensitization of pre-synaptic 5-HT1A and 5-HT1B auto-receptors, further aug-
menting extracellular 5-HT [27]. We thereby conducted a study to see if this signaling 
process in rat brain would be altered by chronic administration of fluoxetine followed 
by 3 days of washout of this SSRI [28]. [3H] AA was intravenously injected in unanes-
thetized rats and used quantitative autoradiography to determine the incorporation 
coefficient k* for AA (regional brain radioactivity/integrated plasma radioactivity), 
a marker of PLA2 activation, in each of 86 brain regions. k* was measured following 
acute i.p. saline or DOI (1.0 mg/kg i.p.), in rats injected for 21 days with 10 mg/kg i.p. 
fluoxetine or saline daily, followed by 3 days without injection. As shown in Figure 3, 
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acute DOI produced statistically significant increments in k* in brain regions with 
high densities of 5-HT2A/2C receptors, but the increments did not differ significantly 
between the chronic fluoxetine- and saline-treated rats. Additionally, chronic fluox-
etine is compared with saline widely and significantly increased baseline values of k*. 
These results suggest that 5-HT2A/2C receptor-initiated AA signaling is unaffected by 
chronic fluoxetine plus 3 days of washout in the rat, but that baseline AA signaling is 
nevertheless upregulated. This upregulation likely occurs because of significant active 
drug in the brain, considering the long brain half-lives of its metabolite, norfluoxetine 
[12]. To further understand SERT regulate brain serotonergic transmission and its 
mediated signaling transduction, we measured PLA2 activation in SERT knockout 
mice (SERT−/−) and their littermate controls (SERT+/+). Following administration 
of 1.5 mg/kg s.c. DOI to unanesthetized mice injected intravenously with radiolabeled 
AA, PLA2 activation, represented as the regional incorporation coefficient k* of AA, 
was determined with quantitative autoradiography in each of 71 brain regions. As 
shown in Figure 4, in SERT+/+ mice, DOI significantly increased k* in 27 regions 
known to have 5-HT2A/2C receptors, including the frontal, motor, somatosensory, 
pyriform and cingulate cortex, white matter, nucleus accumbens, caudate putamen, 
septum, CA1 of the hippocampus, thalamus, and hypothalamus. In contrast, DOI 
did not increase k* significantly in any brain region of SERT−/− mice. Head twitches 
following DOI, which also were measured, were robust in SERT+/+ mice but were 
markedly attenuated in SERT−/− mice. These results show that a lifelong elevation 
of the synaptic 5-HT concentration in SERT−/− mice leads to downregulation of 
5-HT2A/2C receptor-mediated PLA2 signaling via AA and of head twitches, in response 
to DOI. Compared with wild-type mice, DOI-induced k* increments were reduced in 
Figure 3. 
Coronal autoradiographs demonstrating arachidonic acid incorporation coefficients k. Brain of (A) control rat 
given acute saline 3 days after receiving i.p. saline for 21 days; (B) control rat given acute DOI (1.0 mg/kg i.p.), 
3 days after receiving i.p. saline for 21 days; (C) rat given fluoxetine (10 mg/kg i.p. daily) for 21 days, followed by 
3 day washout, and then i.p. Saline on day 24; (D) rat given fluoxetine (10 mg/kg i.p. daily) for 21 days, followed 
by 3 day washout, and then acute DOI (1.0 mg/kg i.p.). k is color-coded. Abbreviations: Fr (IV), frontal cortex, 
layer IV; FrPaM (IV), frontal motor (layer IV); Soms, somatosensory cortex; IPC, interpeduncular nucleus; 
CPU, caudate putamen; CA1, CA2, CA3, DG, regions of the hippocampus; Pir, pyriform cortex; PO, olfactory 
cortex; GrCbG, granular layer, cerebellar gray; CbW, cerebellar white; DR, dorsal raphe; MVe, medial vestibular 
nucleus; Abc, nucleus accumbens. This figure adapted from [28].
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SERT knock out mice [29], but there was no significant effect of 3 weeks of fluoxetine 
plus washout on DOI-induced k* increments in compared with baseline of chronic 
fluoxetine treated rats. The difference suggests that a life-long, but not a 3-week, 
elevation of synaptic 5-HT will downregulate 5-HT2A/2C receptor signaling involving 
PLA2.
In summary, these studies suggest that labeled AA can be used to examine 
in vivo brain PLA2 signaling initiated by a serotonergic drug. Eventually, brain 
5-HT2A/2C-mediated signaling coupled to PLA2 might be imaged in such subjects 
with positron emission tomography [30].
5. Monitoring therapeutic SSRI in patients
Depression is among the most prevalent psychiatric disorders with a highly 
variable treatment response and up to one-third of patients not achieving response 
[31]. SSRIs are the most commonly prescribed antidepressants and the best over-
all treatments for depression patients. However, therapeutic outcomes of SSRIs 
are often far from satisfactory for both patients and prescribing physicians [32]. 
Therefore, after having focused clinical research on the development of new drugs, 
growing evidence suggests that an improved application of available drug may still 
bring substantial benefit to patients [33, 34]. Moreover, there is a gap between the 
available pharmacological knowledge and its utilization in health care. The newest 
initiative to bridge this gap is “Precision Medicine.” It considers individual vari-
ability to build the evidence base needed to guide clinical practice [35]. Therapeutic 
drug monitoring (TDM) is a patient management tool for precision medicine 
[36]. It enables tailoring the dosage of the medications to the individual patient by 
combining the quantification of drug concentration in blood, information on drug 
properties, and patient characteristics [37]. Because patients differ in their ability 
Figure 4. 
Coronal autoradiographs demonstrating incorporation coefficients k* for arachidonic acid, from brain of 
SERT+/+ mouse given saline s.c.; SERT +/+ mouse given DOI (1.5 mg/kg s.c.); SERT−/− mouse given saline; 
SERT+/+ mouse given DOI. k* is color coded. This figure adapted from [29].
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to absorb, distribute, metabolize, and excrete drug due to concurrent disease, 
age, concomitant medication or genetic abnormalities, the drug’s steady-state 
concentration in the body may have a more than 20-fold interindividual variation 
when the same dose of drug is administrated [38, 39]. TDM quantifies the drug’s 
concentration in plasma or serum to adjust the dosage of individual patients, which 
increases probability of response and decreases risk of adverse drug reactions/ 
toxicity [40, 41]. Moreover, TDM has the potential to enhance the cost-effectiveness 
of antidepressant therapy [42–44]. The benefits of TDM for optimization of 
pharmacotherapy, however, can only be obtained when the method is adequately 
integrated into the clinical treatment process. Current TDM use in depression care 
is often suboptimal as demonstrated by systematic studies [45–47]. The suboptimal 
use of TDM wastes laboratory resources and bears the risk of misleading results that 
will adversely influence clinical decision making. Studies on TDM for antidepres-
sant will further specify the information on the imperfect use of TDM [48].
Among SSRIs, citalopram is the most SSRI [13], and some studies reported that 
it is more effective and better tolerated than other drugs for depression but has 
been associated with suicidality and worsening depression especially in adoles-
cents and young adults [49]. Citalopram is strongly recommended for TDM by the 
Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie 
(AFNP) guidelines and was recently upgraded into the level 1 recommendation drug 
[37, 50]. Its reported therapeutic reference ranges (50–110 ng/mL) are established 
and have been quantified. Controlled clinical trials have known beneficial effects 
of TDM, reports on decreased tolerability or intoxications [50]. Fluoxetine strongly 
inhibits 5-HT uptake with minimal effects on other neurotransmitter uptake system 
[51]. Norfluoxetine, an active metabolite of fluoxetine, contributes to the long 
elimination half-life (3-15 days) and overall clinical effect of fluoxetine [12]. TDM 
of fluoxetine is listed as “useful” AFNP guidelines [37, 50]. The therapeutic reference 
range of 120–500 ng/mL includes the quantification of fluoxetine and its long-lasting 
active metabolite, norfluoxetine. The total concentration of fluoxetine and norfluox-
etine in plasma is needed to be determined. Thus, there is a clinical demand for the 
detection of fluoxetine and norfluoxetine when patients are receiving fluoxetine. The 
clinical service for TDM of antidepressants needs to be established.
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